Pulse.

a daily field guide to health research that matters

◆ Console

‹ Sun · 15 Nov 2026
Promising but preliminary

Glucagon-like peptide-1 receptor agonists in adults with overweight/obesity and alcohol use disorder: A retrospective cohort study.

GLP-1 medications show associations with both weight loss and reduced alcohol use in people with alcohol use disorder, suggesting a potential dual benefit worth studying further.

Penn State retrospective cohort investigates GLP-1 RA prescribing in overweight/obese adults with co-existing alcohol use disorder, finding associations with reduced alcohol use alongside weight loss. The NIH NIDA/NIAAA author (Leggio L) lends credibility to this hypothesis; findings are exploratory given non-randomized design but add to emerging evidence for GLP-1 RA as a potential dual-indication therapy.

What the study was

Study design
Retrospective cohort study
Category
Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk
Maturity
Exploratory
Journal
Eur J Intern Med

Why it surfaced

Novel real-world hypothesis generation for GLP-1 RA in AUD; NIH NIDA and Penn State authorship; published in Eur J Intern Med; abstract truncated, full results require primary paper access. High novelty score justified by unpublished clinical indication. Requires prospective RCT confirmation.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.